

Lumito and Offspring Biosciences report promising initial results from pilot study evaluating automated immunohistochemistry platform

Lumito AB (publ) ("Lumito" or the "Company") and Offspring Biosciences Sweden AB ("Offspring Biosciences") today announce promising initial results from the pilot study evaluating Lumito's proprietary tissue labelling and high-sensitivity imaging platform in combination with Offspring Biosciences' automated Immunohistochemistry (IHC) platform.

Offspring Biosciences has transferred Lumito's SCIZYS Erbium manual assay on to the Dx Ultra automated IHC platform, while Lumito has supplied the reagent kits, performed scanning of the stained tissue samples, and jointly with Offspring Biosciences evaluated the results.

The results of the study indicate strong potential for integrating Lumito's SCIZYS Erbium reagent kit into the Discovery Ultra platform with only minor protocol adaptations. To support this transition, targeted modifications were made to align the manual assay with the automated workflow. While further optimisation and protocol refinement are still required, the findings mark an important step toward enabling Lumito's highly sensitive IHC solution on the Discovery Ultra platform. Building on these results, the companies are evaluating alternative workflow configurations to further enhance compatibility, including commercially available system setups and additional protocol customisation options.

"We are very pleased with the promising initial results achieved together with Offspring Biosciences. The study confirms the potential of combining highly standardised automated staining workflows with the SCIZYS platform. The results demonstrate compatibility with an additional autostainer workflow and further broaden the potential applicability of the SCIZYS platform across widely used automated staining systems. While additional optimisation remains, this represents an important step towards enabling automated, quantitative and highly sensitive tissue analysis with greater standardisation and reduced variability," says Sanna Wallenborg, CEO of Lumito.

"We are pleased with the outcome of the pilot study and value the opportunity to work together on this promising application. The next step will be to build on these findings and continue refining the workflow to assess its potential for advanced tissue analysis" says Åsa Johansson, CEO of Offspring Biosciences.

The collaboration entails no financial or commercial obligations for either party beyond the execution and evaluation of the pilot study.

About Offspring Biosciences

Established in 2012, Offspring Biosciences is a cell and tissue focused, research and development contract research organisation, that promotes scientific excellence in support of the biotechnology and pharmaceutical industry.

For further information, please contact:

Sanna Wallenborg, CEO Lumito

E-mail: sw@lumito.se

Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Growth Market under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Lumito and Offspring Biosciences report promising initial results from pilot study evaluating automated immunohistochemistry platform](#)